Exponent (NasdaqGS:EXPO) Q4 2025 Earnings call February 05, 2026 04:30 PM ET Company ParticipantsCatherine Corrigan - President and CEOJoni Konstantelos - Managing DirectorJosh Chan - Executive DirectorRich Schlenker - EVP and CFOTobey Sommer - Managing DirectorTomo Sano - Managing DirectorConference Call ParticipantsAndrew Nicholas - Equity Research AnalystOperatorGood day, and welcome to the Exponent, Inc. Fourth Quarter and Fiscal Year 2025 earnings conference call. All participants will be in listen-onl ...

Arrowhead Pharmaceuticals (NasdaqGS:ARWR) Q1 2026 Earnings call February 05, 2026 04:30 PM ET Company ParticipantsAndrea Newkirk - SVP of Biotechnology Equity ResearchAndy Davis - SVP and Head of Global Cardiometabolic FranchiseChris Anzalone - President and CEODan Apel - CFOEdward Tenthoff - Managing DirectorJames Hamilton - Chief Medical Officer and Head of R&DJason Gerberry - Managing DirectorJoseph Thome - Managing DirectorMani Foroohar - Managing DirectorMike Ulz - Executive DirectorPatrick Trucchio - ...

Financial Data and Key Metrics Changes - The company reported headline revenue growth of 17% and adjusted EPS growth of 46% in Q2 FY 2026, with revenue reaching $164.2 million, up 16.7% from $140.7 million in the prior year quarter [4][13] - Net income increased to $12.2 million from $9.3 million in the prior year quarter, driven by growth in higher margin offshore regions and reduced SG&A expenses as a percentage of revenue [16][17] - Fully diluted EPS rose to $0.83, a 45% increase from $0.57 in the prior year quarter, supported by strong operating performance and fewer diluted shares outstanding [17][19] Business Line Data and Key Metrics Changes - Revenue growth was primarily driven by the health tech vertical, which grew by 35.1%, travel, transportation, and logistics by 20.2%, and retail and e-commerce by 17.2% [14] - The telecommunications vertical saw a decline of 23.1%, marking it as one of the smallest verticals [15] - Health tech now accounts for 17.4% of total revenue, up from 15.1% in the prior year quarter, while telecommunications decreased to 8.7% from 13.1% [20][21] Market Data and Key Metrics Changes - Offshore revenues grew by 16.2% compared to the prior year quarter, comprising 52.3% of total revenue, while onshore revenues expanded to 24% of total revenue from 22% [15][16] - The company continues to win and grow in all geographic markets, with a focus on higher-margin offshore delivery locations positively impacting bottom-line results [15] Company Strategy and Development Direction - The company is focused on expanding its AI capabilities and strategic investments in high-margin verticals, positioning itself as a leader in AI-powered customer experience [9][10] - The recent promotion of Mike Darwal to Chief AI and Digital Officer reflects the company's commitment to enhancing its AI leadership [10][12] - The company aims to maintain a structurally sound business model with a focus on market-leading growth, expanding margins, and strong cash flow generation [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to maintain momentum in the second half of FY 2026, with expectations to raise revenue and adjusted EBITDA guidance [25][26] - The company anticipates a more consistent revenue flow throughout the fiscal year, moving away from historical seasonal spikes [33] Other Important Information - The company achieved a record adjusted EBITDA of $20.7 million, or 12.6% of revenue, reflecting growth in higher-margin offshore locations and services [18][25] - Capital expenditures increased to $11.7 million, or 7.1% of revenue, driven by expansion in offshore regions [22][23] Q&A Session Summary Question: Demand and impact of AI on the industry - Management highlighted that the company has established itself as an AI leader, which aids in winning new clients and enhances operational execution, contributing to market share growth [28][30] Question: Changes in revenue patterns due to business mix - Management noted that the mix shift towards higher-margin verticals may lead to a more consistent revenue flow throughout the year, reducing the historical seasonal decline [32][34] Question: Gross margins and operating expenses - Management acknowledged that while gross margins have decreased year-over-year, SG&A expenses are growing at a slower rate than revenue, indicating operational efficiency [35][36]

Ribbon Communications (NasdaqGS:RBBN) Q4 2025 Earnings call February 05, 2026 04:30 PM ET Company ParticipantsBruce McClelland - CEOFahad Najam - SVP of Investor Relations and Corporate StrategyJohn Townsend - CFOConference Call ParticipantsDave Kang - Senior AnalystMichael Genovese - Senior Research AnalystRustam Kanga - Research Analyst and Vice PresidentRyan Koontz - Senior AnalystTim Savageaux - Managing Director and Senior Research AnalystOperatorGreetings, and welcome to the Ribbon Communications four ...

Financial Data and Key Metrics Changes - Total company revenue for Q4 2025 was $71.7 million, representing a 63% year-over-year increase, while full-year revenue was $277 million, reflecting a 55% growth compared to the previous year [20][21] - Adjusted EBITDA for Q4 was $4.1 million, a significant improvement from a loss of $16.4 million in the same quarter last year, and for the full year, adjusted EBITDA was $12.2 million compared to a loss of $80.4 million in 2024 [21][22] - The net loss for Q4 was $13.6 million, and for the full year, it was $59.5 million [22] Business Line Data and Key Metrics Changes - In the MRD business, full-year revenue grew 46% year-over-year, with clinical testing revenue increasing 64% for the full year and 59% in Q4 [5][8] - clonoSEQ test volume reached 30,038 tests in Q4, up 43% year-over-year, with blood-based testing accounting for 47% of total tests [8][9] - Immune Medicine revenue was $9.8 million in Q4, up from $3.8 million a year ago, primarily driven by data licensing agreements with Pfizer [22][23] Market Data and Key Metrics Changes - The MRD pharma business saw a revenue growth of 20% year-over-year, with multiple myeloma accounting for roughly 70% of sequencing revenue [12] - The average ASP in the U.S. for clonoSEQ tests was $1,307, up 17% year-over-year, and the company expects to reach approximately $1,400 per test in 2026 [10][11] Company Strategy and Development Direction - The company aims to continue driving top-line growth while expanding margins, focusing on MRD revenue growth and profitability [14][27] - In 2026, the company expects clonoSEQ test volumes to grow by more than 30% year-over-year, with a significant shift towards blood-based testing [15][16] - The Immune Medicine business is focusing on generating large-scale proprietary immune receptor data and monetizing this data through partnerships [18][19] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive adjusted EBITDA and free cash flow by the end of 2026, with a focus on disciplined spending and operational efficiency [26] - The company is optimistic about the momentum in MRD and the potential for continued growth in the Immune Medicine sector [27] Other Important Information - The company ended the year with a strong cash position of $227 million, providing flexibility for future investments [22][24] - The company plans to maintain a disciplined capital allocation strategy, with a target net cash burn of $15 million to $20 million for the Immune Medicine business in 2026 [19] Q&A Session Summary Question: Discussion on clonoSEQ volume trends and seasonality - Management acknowledged Q4's strong results and noted that Q1 typically experiences some seasonality due to holidays and weather, but they remain confident in achieving strong sequential growth in Q1 [30][32] Question: Penetration rates in DLBCL and competition - Management highlighted the importance of data generation, guideline advancements, and deepening penetration with pharma to increase market share in DLBCL, where current penetration is low [34][36] Question: Competitive flow cytometry assay and pricing - Management emphasized that flow-based methods are inherently less sensitive than clonoSEQ, which maintains a significant advantage in sensitivity for myeloma testing [40][42] Question: ASP pacing and payer negotiations - Management indicated that ASP growth is expected to be linear, with ongoing negotiations with key payers that could impact ASP realization [43][44] Question: EBITDA guidance for 2026 - Management clarified that they expect to achieve positive adjusted EBITDA by the end of Q4 2026, with MRD expected to contribute positively [46][47] Question: Community and blood-based testing growth assumptions - Management expressed confidence in the potential for further growth in blood-based testing and community penetration, with ongoing investments to drive these areas [50][51] Question: Monetization of the Immune Medicine data - Management discussed the potential for additional data licensing deals and the value of their proprietary dataset in various immunology applications [72][73]

Reddit (NYSE:RDDT) Q4 2025 Earnings call February 05, 2026 04:30 PM ET Company ParticipantsAndrew Boone - Managing DirectorBenjamin Black - Co-Head of Internet Equity ResearchDrew Vollero - CFOJason Helfstein - Managing Director and Head of Internet ResearchJen Wong - COOJesse Rhodes - Head of Investor RelationsJosh Beck - Managing DirectorJustin Post - Managing DirectorNaved Khan - Managing DirectorRich Greenfield - General PartnerRon Josey - Managing DirectorSteve Huffman - Co-founder and CEOConference Ca ...

Knowles (NYSE:KN) Q4 2025 Earnings call February 05, 2026 04:30 PM ET Company ParticipantsJeffrey Niew - CEOJohn Anderson - CFOSarah Cook - VP of Investor RelationsTyler Bomba - Equity Research AssociateWill Gildea - Equity Research AssociateConference Call ParticipantsAnthony Stoss - Senior Research AnalystChristopher Rolland - Senior Equity Analyst in SemiconductorsOperatorGood day, everyone, and welcome to Knowles Corporation's fourth quarter. I would like to hand the conference over to Ms. Sarah Cook. P ...

Arrowhead Pharmaceuticals (NasdaqGS:ARWR) Q1 2026 Earnings call February 05, 2026 04:30 PM ET Company ParticipantsAndrea Newkirk - SVP of Biotechnology Equity ResearchAndy Davis - SVP and Head of Global Cardiometabolic FranchiseChris Anzalone - President and CEODan Apel - CFOEdward Tenthoff - Managing DirectorJames Hamilton - Chief Medical Officer and Head of R&DJason Gerberry - Managing DirectorJoseph Thome - Managing DirectorMani Foroohar - Managing DirectorMike Ulz - Executive DirectorPatrick Trucchio - ...

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $103 million, with a non-GAAP EPS of $0.23 per share, marking a 6% increase in full-year revenue and an 8% growth in non-GAAP EPS compared to the previous year [4][15] - Cash flow from operations reached $112 million for the year, an increase of $30 million from the prior year [4][20] - Non-GAAP gross margin for the year was 55.1%, up 70 basis points from the prior year [19] Business Line Data and Key Metrics Changes - Industrial revenue was down 23% sequentially in Q4 but had a strong year overall with a 15% increase [15][19] - Consumer revenue, primarily from appliances, decreased by 13% sequentially in Q4 due to excess inventory but was slightly up for the full year [16][19] - Communications revenue grew 15% sequentially in Q4, driven by new design ramps in cell phone and India 5G broadband [16] Market Data and Key Metrics Changes - The industrial market is expected to be the fastest-growing segment in 2026, with strong Q1 expectations [6] - Revenue outside of cell phone applications averaged 12% growth over the past two years, with industrial revenue growing 15% in 2025 [8] - The consumer market continues to face headwinds, including low existing home sales in the U.S. and ongoing softness in the Chinese housing market [5] Company Strategy and Development Direction - The company is focusing on aligning expenses with revenue through workforce restructuring, reducing global workforce by about 7% [4][5] - Investment priorities are shifting towards markets like AI data centers, industrial, and automotive, leveraging expertise to solve power challenges [7][8] - The company aims to enhance customer-focused product development and accelerate time to market [12][39] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about returning to growth in 2026, with plans for similar growth levels year over year [35] - The consumer business is still facing challenges, but improvements are expected if housing market conditions improve [34][35] - The company is committed to maintaining rigorous operational efficiency and focusing on high-growth segments [22][45] Other Important Information - Non-GAAP operating expenses for Q4 were $45 million, below the outlook of $47 million, reflecting cost control measures [17] - The effective tax rate for the quarter was expected to be in the range of 7%-8% due to changes in tax credits [21] Q&A Session Summary Question: Plans to address high channel inventory - Management acknowledged the need to reduce channel inventory and is focused on achieving a healthier level through rigorous planning [25][26] Question: Long-term growth from high power, automotive, and data center segments - Management indicated that while GaN is already meaningful, automotive and data center contributions will take more time to materialize [28][30] Question: Current demand cycle status - Management believes the consumer business is still facing headwinds but sees potential for improvement depending on housing market conditions [33][34] Question: Impact of restructuring on R&D and time to market - Management emphasized the importance of restructuring in enhancing agility and customer-centricity in product development [37][39] Question: Revenue expectations from automotive segment - Management suggested that automotive revenue could materialize in the next 12 to 18 months, depending on design wins [42][43] Question: Future of consumer segment - Management confirmed that the consumer segment remains important, with ongoing support despite current challenges [46][47]

IBEX (NasdaqGM:IBEX) Q2 2026 Earnings call February 05, 2026 04:30 PM ET Company ParticipantsBob Dechant - CEO and DirectorGreg Bradbury - Head of Investor RelationsTaylor Greenwald - CFOConference Call ParticipantsDavid Koning - Senior Research AnalystOperatorWelcome to the ibex second quarter FY 2026 earnings conference call. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. After the speaker's presentation, there will be a question-and- ...